Phase 1 Pancreatic Cancer Trial, Recruiting NCT07114939 Sponsor: Abramson Cancer Center at Penn Medicine Condition: Pancreatic Cancer
Back to Pancreatic Cancer

Phase 1 Pancreatic Cancer Trial, Recruiting

NCT07114939
Recruiting Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged 18 or older
  • People who have been diagnosed with a pancreatic neuroendocrine tumor that has spread to other parts of the body or cannot be surgically removed, and is classified as grade 1, grade 2, or grade 3
  • People who have at least one tumor or lesion measuring 1.5 cm or larger, as seen on a scan (such as a CT, MRI, PET, or ultrasound)
  • People who are currently receiving treatment for their condition, as well as those who are not currently receiving any treatment
  • People who are willing to allow previously collected tumor tissue samples (from another study, a tissue bank, or a clinical procedure) to be used for this research
  • People who are willing to give written consent to take part and who are able to understand the nature of the study

Who may not be able to join:

  • People who have received a liver-directed therapy that treated all of their known disease, and whose disease has not yet come back or progressed
  • People who are unable to tolerate imaging scans, in the opinion of the treating doctor or investigator
  • People who are pregnant or breastfeeding (a urine pregnancy test will be done before certain study procedures for people who could become pregnant)
  • People who have a current medical condition, illness, or disorder that a doctor considers could put the participant at risk or affect their ability to take part in the study safely
  • Children, prisoners, and people who are unable to give informed consent are not eligible to participate

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 14 July 2026
Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Austin Pantel, MD, University of Pennsylvania

Phone: 215-573-6569

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 1
Sponsor
Abramson Cancer Center at Penn Medicine
Registry
ClinicalTrials.gov
Start date
1 October 2025
Est. completion
1 September 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

[18F]FTT SUV in PanNETS

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 14 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov